



FOR IMMEDIATE RELEASE

ImmusanT Welcomes Michael Cooreman, M.D., Ph.D., as Chief Medical Officer and Anita Treohan as Director of Clinical Operations

CAMBRIDGE, Mass. – Oct. 5, 2015 – [ImmusanT, Inc.](#), a company focused on restoring tolerance to gluten and overcoming the need for gluten-free diet in patients with celiac disease, today announced the appointment of Michael Cooreman, M.D., Ph.D., as Chief Medical Officer and Anita Treohan as Director of Clinical Operations.

Dr. Cooreman brings to ImmusanT extensive experience in clinical development and translational medicine. As Chief Medical Officer, he will lead all clinical development programs, including the development of Nexvax2[®], ImmusanT's lead product candidate for the treatment of celiac disease. Ms. Treohan joins the company with diverse global clinical development and strategic experience across multiple therapeutic areas. As Director of Clinical Operations, Ms. Treohan will be responsible for the management of ImmusanT's clinical programs, including the upcoming Phase 2 trials of Nexvax2.

"ImmusanT is expanding our clinical team to support the advancement of our therapeutics and diagnostics pipeline, and we are thrilled to welcome Michael and Anita on board," said Leslie J. Williams, President and CEO of ImmusanT. "Their wide-ranging experience in global clinical development will provide immense support for the accelerated development of Nexvax2 and our entire product pipeline. We look forward to their contributions as we continue development of this disease-modifying immunotherapy, as well as development of our companion diagnostic and universal standalone, blood-based diagnostic for celiac disease."

Dr. Cooreman joins ImmusanT from Mitsubishi Tanabe, where he served as Executive Director for Clinical Research and Head of Metabolism, Infectious Diseases and Oncology. Previously, he oversaw the clinical programs for a second-generation protease inhibitor and NS5A inhibitor for hepatitis C at Merck as Executive Director of Hepatology, Infectious Diseases and Late-stage Clinical Development. Prior to his role at Merck, Dr. Cooreman was the head of Takeda's translational medicine group and before that, served in the same role at Ikaria (now part of Mallinckrodt Pharmaceuticals). Earlier in his career, as a project and medical leader at the Novartis Institutes for BioMedical Research, he developed and oversaw several programs from IND-enabling studies through Phase 3 development, which included monoclonal antibodies (anti-IL17 agents) and small molecules for the treatment of rheumatoid arthritis, psoriasis and hepatitis C. Dr. Cooreman earned his doctor of medicine at the University of Leuven Medical School in Belgium and his doctorate in microbiology at Heinrich Heine University in Duesseldorf, Germany.

Most recently, Ms. Treohan served as Director of Clinical Operations at FORUM Pharmaceuticals Inc., where she was the operational lead for several clinical development assets for neurodegenerative and psychiatric diseases. Before working at FORUM, Ms. Treohan held various clinical operations and development roles of increasing responsibility at Pfizer, Merck, GlaxoSmithKline, Charles River Laboratories Clinical Services and Dana-Farber Cancer Institute. Ms. Treohan holds a Master of Public Health in Epidemiology/Biostatistics and Social Behavioral Sciences from Boston University and a Bachelor's degree in Biology from Emory University.

About ImmusanT Inc.

ImmusanT is a privately held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing [Nexvax2[®]](#), a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management. ImmusanT's targeted immunotherapy discovery platform can be

applied to a variety of epitope-specific autoimmune diseases. Founded in 2010, ImmusanT is backed by [Vatera Healthcare Partners](#). More information may be found at www.ImmusanT.com, or follow [ImmusanT](#) on Twitter.

ImmusanT Contact:

Leslie Williams
President and CEO
(617) 299-8399 Ext. 201
Leslie@ImmusanT.com

Media Contact:

Chris Erdman
MacDougall Biomedical Communications
(781) 235-3060
cerdman@macbiocom.com

###